Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease
news
Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board Observer
Newton, Massachusetts, June 23, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that Dietmar Berger, M.D., Ph.D., currently the Chief Medical Officer and Head of Global Development at Sanofi will contribute his considerable experience to the company’s Board of
June 23, 2022
Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board ObserverPress Releases